Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

ARWR

Arrowhead Pharmaceuticals Inc

Feb 06 • 04:00PM ET

64.52

-0.12 -0.19 %

Healthcare • Biotechnology • USA • NASD

Feb 06, 10:38 AMArrowhead posts its first profitable quarter on milestones (Q1 net income $30.8M), beats fiscal Q4 2025 with non-GAAP EPS $0.22 and revenue $264.0M, launches FDA-approved FCS drug REDEMPLO with strong early uptake (100+ prescriptions), fortifies its balance sheet, and will join the S&P MidCap 400 before the Feb. 9 open.

Peers: ALNY IONS SRPT NBIX DTIL VRTX RGNX CRSP EDIT NTLA

| Held by: IJR VTI IWM VB VBK VXF XBI SPSM IJT IWO

Index	RUT	P/E	41.95	EPS (ttm)	1.54	Insider Own	7.01%	Shs Outstand	137.39M	Perf Week	-6.94%
Market Cap	9.03B	Forward P/E	-	EPS next Y	-4.32	Insider Trans	-5.50%	Shs Float	130.20M	Perf Month	-1.78%
Enterprise Value	8.80B	PEG	-	EPS next Q	-1.05	Inst Own	78.67%	Short Float	8.29%	Perf Quarter	60.06%
Income	202.26M	P/S	8.28	EPS this Y	-30960.38%	Inst Trans	4.57%	Short Ratio	3.98	Perf Half Y	301.74%
Sales	1.09B	P/B	15.59	EPS next Y	-39.09%	ROA	15.45%	Short Interest	10.79M	Perf YTD	-2.82%
Book/sh	4.14	P/C	9.86	EPS next 5Y	-	ROE	65.14%	52W High	76.76 -15.95%	Perf Year	218.30%
Cash/sh	6.55	P/FCF	27.62	EPS past 3/5Y	80.60% 57.10%	ROIC	16.73%	52W Low	9.57 574.19%	Perf 3Y	82.83%
Dividend Est.	-	EV/EBITDA	27.02	Sales past 3/5Y	50.52% 56.63%	Gross Margin	97.70%	Volatility	8.64% 5.81%	Perf 5Y	-19.11%
Dividend TTM	-	EV/Sales	8.07	EPS Y/Y TTM	130.44%	Oper. Margin	27.55%	ATR (14)	4.32	Perf 10Y	1754.02%
Dividend Ex-Date	-	Quick Ratio	3.38	Sales Y/Y TTM	43539.24%	Profit Margin	18.54%	RSI (14)	45.69	Recom	1.79
Dividend Gr. 3/5Y	- -	Current Ratio	3.38	EPS Q/Q	115.80%	SMA20	-3.82%	Beta	1.23	Target Price	82.00
Payout	-	Debt/Eq	1.21	Sales Q/Q	10461.32%	SMA50	-2.23%	Rel Volume	8.74	Prev Close	64.64
Employees	711	LT Debt/Eq	1.13	Earnings	Feb 05 AMC	SMA200	86.12%	Avg Volume	2.71M	Price	64.52
IPO	Dec 16, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	491.40% 23.41%	Trades		Volume	23,689,439	Change	-0.19%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-05-24	Initiated	Goldman	Neutral	$31
Dec-04-23	Initiated	BofA Securities	Buy	$29
Sep-19-23	Initiated	Citigroup	Neutral	$33
Jul-21-23	Initiated	TD Cowen	Outperform
May-12-23	Downgrade	SVB Securities	Outperform → Market Perform	$40
Apr-26-23	Initiated	SMBC Nikko	Outperform	$80
Apr-12-23	Upgrade	SVB Securities	Market Perform → Outperform	$21 → $35
Mar-21-23	Initiated	Bernstein	Mkt Perform	$27
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$41
May-11-22	Upgrade	Robert W. Baird	Neutral → Outperform	$71 → $60
Jan-19-22	Resumed	Goldman	Buy	$90 → $85
Aug-06-21	Reiterated	Chardan Capital Markets	Buy	$97 → $94
Jun-04-21	Resumed	Robert W. Baird	Neutral	$85
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$90 → $95
Dec-21-20	Downgrade	Robert W. Baird	Outperform → Neutral	$75
Dec-16-20	Initiated	UBS	Buy	$95
Nov-19-20	Initiated	Citigroup	Buy	$90
May-13-20	Initiated	RBC Capital Mkts	Outperform	$62
May-08-20	Upgrade	Oppenheimer	Perform → Outperform	$58
Apr-15-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$55 → $60

Show Previous Ratings

Feb-06-26 12:04AM	Arrowhead Pharmaceuticals Inc (ARWR) Q1 2026 Earnings Call Highlights: Strong Financial ... (GuruFocus.com)
Feb-05-26 08:06PM	Arrowhead Pharmaceuticals Q1 Earnings Call Highlights (MarketBeat) -5.02%
04:54PM	Arrowhead Research: Fiscal Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results (Business Wire)
Feb-04-26 06:15PM	Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 (PR Newswire) -5.66%
01:31PM	Loading…
Jan-29-26 01:31PM	Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration (PR Newswire) +5.40%
Jan-27-26 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia (Business Wire)
Jan-22-26 03:20AM	Piper Sandler Highlights Arrowhead Pharmaceuticals, Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data (Insider Monkey)
Jan-20-26 04:30PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results (Business Wire)
Jan-19-26 05:18PM	Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory (Insider Monkey)
Jan-12-26 05:43PM	Arrowhead Pharmaceuticals Touts Rudemplo Launch, Obesity RNAi Data and $920M Cash at JPM Conference (MarketBeat)
Jan-11-26 01:09AM	Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR) (Insider Monkey)
Jan-07-26 11:05PM	Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants (Business Wire) -7.23%
07:30AM	Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China (Business Wire)
Jan-06-26 06:14PM	Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock (Business Wire) +10.85%
04:29PM	Loading…
04:29PM	Arrowhead Says Its Gene Silencer Doubled Zepbound's Weight Loss (Investor's Business Daily)
11:26AM	Zepbound Boost Gets a Lift From Arrowhead's Drug. The Question Is Whether Patients Will Pay. (Barrons.com)
07:30AM	Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition (Business Wire)
Jan-05-26 07:30AM	Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire) -5.77%
Dec-23-25 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events (Business Wire)
Dec-15-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -5.54%
Dec-12-25 08:00AM	Arrowhead price target raised to $80 from $52 at RBC Capital (TipRanks)
Dec-08-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies (Business Wire) +11.65%
Dec-02-25 07:30AM	Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia (Business Wire)
Dec-01-25 04:00PM	Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences (Business Wire) +6.74%
Nov-27-25 06:51AM	Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval (Insider Monkey)
Nov-26-25 07:16PM	Why Arrowhead Pharmaceuticals Stock Surged by Over 23% Today (Motley Fool) +23.34% -8.68%
05:47AM	Novartis cuts hundreds of jobs; Novos dual-acting diabetes drug heading to Phase 3 (BioPharma Dive)
12:00AM	Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ... (GuruFocus.com)
Nov-25-25 04:00PM	Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results (Business Wire) +5.72%
01:08PM	Loading…
01:08PM	Sarepta's Stock Rises on Positive Updates on DM1 Therapy (Zacks)
Nov-24-25 07:30AM	Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics (Business Wire) +9.42%
Nov-19-25 12:52PM	Arrowhead nets first commercial win as siRNA drug garners FDA approval (Pharmaceutical Technology)
Nov-18-25 11:52AM	Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) (Business Wire)
07:39AM	RNAi biotech Arrowhead wins first FDA approval (BioPharma Dive)
Nov-06-25 04:30PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results (Business Wire)
Nov-04-25 01:46PM	SRPT Q3 Earnings Miss Estimates, Stock Dips on DMD Study Failure (Zacks)
07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences (Business Wire)
Oct-28-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Oct-21-25 07:30AM	Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis (Business Wire)
Sep-11-25 07:30AM	Arrowhead Pharmaceuticals Files Complaint for Declaratory Judgment Against Ionis Pharmaceuticals (Business Wire)
Sep-10-25 11:06AM	NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline (Zacks)
07:30AM	Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies (Business Wire)
12:59AM	H.C. Wainwright Reiterated a Buy on Arrowhead Pharmaceuticals (ARWR) (Insider Monkey)
Sep-05-25 07:44AM	Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal (Motley Fool)
Sep-03-25 04:14PM	Arrowhead Lands Billion-Dollar Biotech Deal: Stock Soars Double-Digits (GuruFocus.com) +8.26%
09:42AM	NVS Inks a Licensing Deal With Arrowhead for siRNA Therapy (Zacks)
Sep-02-25 09:53AM	Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion (Investor's Business Daily) +16.57%
08:03AM	Novartis thinks Arrowhead brain drug can succeed where others couldnt (BioPharma Dive)
07:30AM	Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement (Business Wire)
Aug-27-25 07:30AM	Arrowhead Pharmaceuticals to Participate in Upcoming September 2025 Conferences (Business Wire)
Aug-21-25 09:33AM	Sarepta Gets Breathing Room in $700 Million Debt Restructure (Bloomberg)
Aug-20-25 04:41PM	Goodbye, Mag 7! These 3 Buy-Rated Small-Cap Stocks Are Starting to Outperform. (Barchart)
Aug-18-25 12:31PM	Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue (Insider Monkey)
Aug-15-25 10:42AM	Stock Market Today: Dow approaches fresh record despite disappointing economic data drop (TheStreet) +9.21%
Aug-14-25 04:18PM	Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives (Investor's Business Daily) -6.05%
11:41AM	Sarepta Sells Biotech Stake to Raise Cash as Elevidys Troubles Hit Home (Barrons.com)
11:24AM	Sarepta Sells Arrowhead Stake to Fund Milestone Payment (Zacks)
07:29AM	Sarepta sells Arrowhead shares as partnership, debt payments loom (BioPharma Dive)
Aug-13-25 04:12PM	Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment (Business Wire) +12.30%
04:10PM	Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics (Business Wire)
Aug-07-25 04:10PM	Arrowhead Research: Fiscal Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2025 Third Quarter Results (Business Wire)
09:29AM	Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries (Zacks)
Aug-04-25 11:07AM	Sarepta to Report Q2 Earnings: What's in Store for the Stock? (Zacks)
Aug-01-25 06:30AM	Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi (Business Wire)
Jul-31-25 11:58AM	Arrowhead Pharmaceuticals, Inc. (ARWR) Secures $100M Milestone from Sarepta in RNAi Breakthrough Deal (Insider Monkey)
Jul-30-25 08:30AM	Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval (BioPharma Dive)
Jul-28-25 04:55PM	Stocks Hold at Record, Dollar Jumps on Trade Hopes: Markets Wrap (Bloomberg)
07:30AM	Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics (Business Wire)
Jul-24-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jul-23-25 08:00AM	Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics (Business Wire) +6.42%
Jul-22-25 03:40PM	Arrowhead Pharma (ARWR) Shares Dragged by Sarepta Concerns (Insider Monkey)
Jul-21-25 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter Results (Business Wire) -12.23%
Jul-17-25 10:58AM	SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots (Zacks)
Jul-16-25 04:01PM	Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label (Business Wire)
Jul-09-25 05:32AM	Arrowhead doses first patient in Phase III trial of zodasiran for HoFH treatment (Clinical Trials Arena) +7.64%
Jul-08-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia (Business Wire)
Jul-01-25 05:32AM	Chronic Hepatitis B Market Analysis and Forecast, 2025-2035 \| Diagnostic Advances, Innovative Therapies, and Rising Awareness Bolster Growth (GlobeNewswire)
Jun-23-25 07:30AM	Arrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of Plozasiran (Business Wire)
Jun-05-25 05:10AM	Jim Cramer on Arrowhead Pharmaceuticals (ARWR): "It Doesn't Make Any Money" (Insider Monkey)
Jun-03-25 08:28PM	Lightning Round: Buy Dover right now, says Jim Cramer (CNBC TV)
05:37AM	Arrowhead commences dosing in Phase I/IIa obesity treatment trial (Clinical Trials Arena)
Jun-02-25 07:30AM	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity (Business Wire)
May-29-25 07:30AM	Arrowhead Pharmaceuticals to Participate in June 2025 Investor Conferences (Business Wire) +8.10%
May-13-25 03:07AM	Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ... (GuruFocus.com) +9.38%
May-12-25 04:10PM	Arrowhead Research: Fiscal Q2 Earnings Snapshot (Associated Press Finance) +7.21%
04:01PM	Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results (Business Wire)
May-07-25 02:14PM	Sarepta: ELEVIDYS DMD Treatment Setback Brings Downgrade To Hold Rating (Seeking Alpha)
12:14PM	Sarepta Therapeutics: Lowered Elevidys Guidance Warrant Ratings Downgrade (Seeking Alpha)
08:31AM	SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut (Zacks)
07:30AM	Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences (Business Wire)
May-05-25 07:49AM	Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential (Insider Monkey)
Apr-30-25 04:01PM	Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results (Business Wire)
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Apr-19-25 05:30AM	ClearBridge Small Cap Strategy Q1 2025 Commentary (Seeking Alpha)
Apr-15-25 04:00PM	Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer (Business Wire) -11.81%
Apr-04-25 04:30PM	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) (Business Wire) -11.44%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-24-25 08:25AM	How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion (Zacks)

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
O'Brien Patrick	COO	Jan 05 '26	Sale	63.11	49,493	3,123,349	474,908	Jan 05 09:50 PM
Hamilton James C	Chief Medical Officer	Jan 05 '26	Sale	63.11	40,164	2,534,661	171,958	Jan 05 09:41 PM
Anzalone Christopher Richard	Chief Executive Officer	Jan 02 '26	Sale	66.10	13,187	871,703	3,792,739	Jan 05 09:39 PM
James Hamilton	Officer	Jan 05 '26	Proposed Sale	63.09	39,728	2,506,627		Jan 05 04:59 PM
Patrick O'Brien	Officer	Jan 05 '26	Proposed Sale	63.10	49,493	3,123,172		Jan 05 04:58 PM
Christopher Anzalone	Officer	Jan 02 '26	Proposed Sale	66.10	13,187	871,668		Jan 02 04:04 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 29 '25	Option Exercise	6.15	51,726	318,115	3,857,652	Dec 30 05:46 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 29 '25	Sale	69.13	51,726	3,575,575	3,805,926	Dec 30 05:46 PM
Ferrari Mauro	Director	Dec 26 '25	Sale	70.00	7,530	527,100	69,053	Dec 30 05:46 PM
Christopher Anzalone	Officer	Dec 29 '25	Proposed Sale	69.13	51,726	3,575,575		Dec 29 04:23 PM
Mauro Ferrari	Director	Dec 26 '25	Proposed Sale	70.00	7,530	527,070		Dec 29 04:03 PM
Waddill William D.	Director	Dec 19 '25	Sale	67.65	8,367	566,038	56,563	Dec 23 06:01 PM
Vakiener Victoria	Director	Dec 19 '25	Sale	67.68	10,040	679,491	35,723	Dec 23 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 19 '25	Sale	67.66	13,445	909,683	3,818,512	Dec 23 06:01 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 22 '25	Sale	68.44	12,586	861,340	3,805,926	Dec 23 06:01 PM
OLUKOTUN ADEOYE Y	Director	Dec 19 '25	Sale	67.66	10,000	676,623	33,600	Dec 23 06:01 PM
Christopher Anzalone	Officer	Dec 22 '25	Proposed Sale	68.43	12,586	861,319		Dec 22 04:00 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 17 '25	Sale	64.04	85,000	5,443,462	3,831,957	Dec 19 06:56 PM
Christopher Anzalone	Officer	Dec 19 '25	Proposed Sale	67.66	13,445	909,632		Dec 19 04:08 PM
William Waddill	Director	Dec 19 '25	Proposed Sale	67.65	8,367	566,001		Dec 19 04:07 PM
Adeoye Olukotun	Director	Dec 19 '25	Proposed Sale	67.66	10,000	676,589		Dec 19 04:07 PM
Victoria Vakiener	Director	Dec 19 '25	Proposed Sale	67.68	10,040	679,464		Dec 19 04:06 PM
Christopher Anzalone	Officer	Dec 17 '25	Proposed Sale	64.04	85,000	5,443,253		Dec 17 05:11 PM
Christopher Anzalone	Officer	Dec 16 '25	Proposed Sale	62.58	54,298	3,398,142		Dec 16 04:47 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 15 '25	Sale	68.85	130,000	8,950,615	3,971,255	Dec 16 01:14 PM
Anzalone Christopher Richard	Chief Executive Officer	Dec 16 '25	Sale	62.58	54,298	3,398,187	3,916,957	Dec 16 01:14 PM
Christopher Anzalone	Officer	Dec 15 '25	Proposed Sale	68.85	130,000	8,950,580		Dec 15 04:50 PM
PERRY MICHAEL S	Director	Dec 05 '25	Sale	61.03	16,250	991,738	115,240	Dec 09 06:04 PM
Michael Perry	Director	Dec 05 '25	Proposed Sale	60.99	16,250	991,129		Dec 05 04:00 PM
Ferrari Mauro	Director	Nov 28 '25	Sale	56.39	8,750	493,412	68,764	Dec 01 06:10 PM
Mauro Ferrari	Director	Nov 28 '25	Proposed Sale	56.35	8,750	493,062		Nov 28 01:19 PM
Hamilton James C	Chief Medical Officer	Oct 01 '25	Sale	35.00	20,000	700,000	212,122	Oct 03 06:15 PM
James Hamilton	Officer	Oct 01 '25	Proposed Sale	35.00	20,000	700,015		Oct 01 03:44 PM
Hamilton James C	Chief Medical Officer	Sep 12 '25	Sale	30.00	15,000	450,000	232,122	Sep 16 06:06 PM
Hamilton James C	Officer	Sep 12 '25	Proposed Sale	30.00	15,000	449,970		Sep 12 04:33 PM
Hamilton James C	Chief Medical Officer	Sep 02 '25	Sale	25.00	15,000	375,000	247,122	Sep 04 05:37 PM
Hamilton James C	Officer	Sep 02 '25	Proposed Sale	25.00	15,000	374,970		Sep 02 05:12 PM
Hamilton James C	Chief Medical Officer	Aug 15 '25	Sale	20.00	9,389	187,780	262,122	Aug 15 05:59 PM
Hamilton James C	Chief Medical Officer	Aug 13 '25	Sale	20.00	611	12,220	271,511	Aug 15 05:59 PM
Hamilton James C	Officer	Aug 15 '25	Proposed Sale	20.00	9,389	187,750		Aug 15 03:42 PM
Sarepta Therapeutics, Inc.	Shareholder	Aug 13 '25	Proposed Sale	19.99	9,265,312	185,213,587		Aug 13 08:55 PM
Hamilton James C	Officer	Aug 13 '25	Proposed Sale	19.95	611	12,190		Aug 13 05:57 PM
Myszkowski Kenneth Allen	Officer	Jul 10 '25	Proposed Sale	19.04	40,000	761,709		Jul 10 04:30 PM
Anzalone Christopher Richard	Chief Executive Officer	Apr 11 '25	Sale	11.49	50,800	583,692	3,921,255	Apr 11 06:20 PM
Anzalone Christopher Richard	Chief Executive Officer	Apr 10 '25	Sale	10.87	50,000	543,500	3,972,055	Apr 11 06:20 PM
Anzalone Christopher Richard	Chief Executive Officer	Apr 09 '25	Sale	10.07	40,322	406,145	4,022,055	Apr 11 06:20 PM
Anzalone Christopher Richard	Officer	Apr 11 '25	Proposed Sale	11.49	50,800	583,751		Apr 11 04:29 PM
Anzalone Christopher Richard	Officer	Apr 10 '25	Proposed Sale	10.86	50,000	543,215		Apr 10 04:35 PM
Anzalone Christopher Richard	Officer	Apr 09 '25	Proposed Sale	10.07	40,322	406,057		Apr 09 04:44 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 13 '25	Sale	15.07	51,425	774,975	4,062,377	Mar 17 05:45 PM
Anzalone Christopher Richard	Officer	Mar 13 '25	Proposed Sale	15.07	51,425	774,785		Mar 13 04:46 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 03 '25	Option Exercise	7.75	166,667	1,291,669	3,940,469	Mar 05 06:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 04 '25	Option Exercise	7.75	133,333	1,033,331	4,073,802	Mar 05 06:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 03 '25	Sale	18.03	166,667	3,005,006	3,907,135	Mar 05 06:32 PM
Anzalone Christopher Richard	Chief Executive Officer	Mar 04 '25	Sale	17.02	133,333	2,269,328	3,773,802	Mar 05 06:32 PM
Anzalone Christopher Richard	Officer	Mar 04 '25	Proposed Sale	17.02	133,333	2,268,742		Mar 04 05:48 PM
Anzalone Christopher Richard	Officer	Mar 03 '25	Proposed Sale	18.03	166,667	3,004,203		Mar 03 05:09 PM

Open in Screener

TERN

Terns Pharmaceuticals Inc

Feb 06 • 04:00PM ET

37.77

+2.43 6.88 %

Healthcare • Biotechnology • USA • NASD

TERN Terns Pharmaceuticals Inc daily Stock Chart

Peers: MDGL VKTX AKRO MNOV LGND GLMD BCRX XBIT ACAD AMRN

| Held by: VTI IWM VXF IWN IBB VTWO SCHA IWC IHE DFAS

Index	RUT	P/E	-	EPS (ttm)	-1.03	Insider Own	13.40%	Shs Outstand	106.33M	Perf Week	9.16%
Market Cap	4.02B	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-1.16%	Shs Float	92.08M	Perf Month	-5.58%
Enterprise Value	3.72B	PEG	-	EPS next Q	-0.30	Inst Own	69.64%	Short Float	17.54%	Perf Quarter	107.64%
Income	-94.44M	P/S	-	EPS this Y	3.13%	Inst Trans	-3.55%	Short Ratio	4.73	Perf Half Y	569.68%
Sales	0.00M	P/B	11.64	EPS next Y	-9.10%	ROA	-27.78%	Short Interest	16.15M	Perf YTD	-6.51%
Book/sh	3.25	P/C	13.58	EPS next 5Y	-6.52%	ROE	-29.12%	52W High	48.26 -21.74%	Perf Year	710.52%
Cash/sh	2.78	P/FCF	-	EPS past 3/5Y	17.43% 16.38%	ROIC	-33.18%	52W Low	1.87 1925.20%	Perf 3Y	322.48%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	7.73% 6.37%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	12.45%	Oper. Margin	-	ATR (14)	2.28	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	19.52	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.12	Recom	1.10
Dividend Gr. 3/5Y	- -	Current Ratio	19.52	EPS Q/Q	4.75%	SMA20	5.58%	Beta	-0.27	Target Price	54.22
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	2.02%	Rel Volume	0.36	Prev Close	35.34
Employees	59	LT Debt/Eq	0.00	Earnings	Nov 10 AMC	SMA200	155.45%	Avg Volume	3.42M	Price	37.77
IPO	Feb 05, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.26% -	Trades		Volume	1,246,129	Change	6.88%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-25	Upgrade	H.C. Wainwright	Neutral → Buy	$20
Nov-03-25	Upgrade	William Blair	Mkt Perform → Outperform
Oct-15-25	Initiated	Truist	Buy	$20
Sep-17-25	Initiated	Barclays	Overweight	$15
Sep-04-25	Resumed	H.C. Wainwright	Neutral
Feb-28-25	Initiated	William Blair	Mkt Perform
Oct-31-24	Initiated	Oppenheimer	Outperform	$82
Jun-22-23	Initiated	Mizuho	Buy	$16
Jun-07-23	Initiated	Jefferies	Buy	$18
May-31-23	Initiated	ROTH MKM	Buy	$23
May-08-23	Initiated	BMO Capital Markets	Outperform	$18
Feb-14-23	Initiated	JMP Securities	Mkt Outperform	$17
Feb-07-23	Initiated	UBS	Buy	$19
Sep-12-22	Initiated	H.C. Wainwright	Neutral	$6
Sep-14-21	Resumed	Goldman	Buy	$21
Mar-02-21	Initiated	JP Morgan	Overweight	$32
Mar-02-21	Initiated	Goldman	Buy	$29
Mar-02-21	Initiated	Cowen	Outperform

Show Previous Ratings

Feb-04-26 09:55AM	Wall Street Analysts See a 50.91% Upside in Terns Pharmaceuticals (TERN): Can the Stock Really Move This High? (Zacks) -6.39%
Feb-02-26 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.42%
04:16AM	Terns Pharmaceuticals (TERN) Eyes Expansion Beyond China Amid Strong Analyst Sentiment (Insider Monkey)
Jan-23-26 05:27AM	Novo climbs higher on strong Wegovy pill launch; Terns tweaks leukemia drug deal (BioPharma Dive)
Jan-15-26 11:35AM	Wall Street Forecasts 42.31% Upside To Terns Pharmaceuticals, Inc. (TERN) (Insider Monkey)
01:00AM	Loading…
Jan-11-26 01:00AM	Citizens Maintains An Outperform Rating On Terns Pharmaceuticals, Inc. (TERN) (Insider Monkey)
Jan-07-26 04:05PM	Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -5.58%
Jan-02-26 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Dec-19-25 03:14PM	Jim Cramer Highlights Massive Gains for Terns Pharmaceuticals Shareholders (Insider Monkey)
Dec-15-25 06:47PM	Terns CEO Amy Burroughs talks cancer drug trial win (CNBC TV)
Dec-14-25 02:40PM	Terns Pharmaceuticals (TERN) Climbs 53% on Stellar Leukemia Treatment Trial (Insider Monkey)
Dec-11-25 04:05PM	Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) +5.56%
Dec-09-25 11:30PM	Terns Announces Pricing of Upsized $650 Million Public Offering (GlobeNewswire) +5.82%
03:31PM	Cancer Study Buoys These Small Biotechs (Barrons.com)
02:23PM	Terns (TERN) Hits All-Time High on Stellar Leukemia Treatment Results (Insider Monkey)
06:12AM	Loading…
06:12AM	Terns Announces Proposed Public Offering (GlobeNewswire)
Dec-08-25 02:45PM	Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting (GlobeNewswire) +37.02%
Dec-04-25 07:57AM	These stocks are new additions to Mizuhos Americas Top Picks list (Investing.com)
Nov-23-25 07:02AM	BMO Believes Market Undervalues Terns Pharmaceuticals (TERN) Despite Strong Trial Data (Insider Monkey)
Nov-18-25 12:43AM	Terns Pharmaceuticals (TERN) Soars to New Record High of $26.12 (Insider Monkey) +7.82%
Nov-17-25 12:15PM	William Blair Reiterates a Buy on Terns Pharmaceuticals (TERN) (Insider Monkey) +13.30%
Nov-14-25 04:05PM	Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London (GlobeNewswire) +8.83%
Nov-10-25 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +7.64%
Nov-04-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +24.23%
Nov-03-25 09:05AM	Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting (GlobeNewswire) +69.85%
Oct-24-25 04:58AM	Chugai buys a kidney biotech; ICER targets rising launch prices (BioPharma Dive)
Oct-21-25 04:05PM	Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity (GlobeNewswire) -5.80%
Oct-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Sep-21-25 10:45AM	2 Under-the-Radar Stocks That Could Soar (Motley Fool)
Aug-21-25 04:05PM	Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025 (GlobeNewswire) +7.30%
09:55AM	Loading…
Aug-07-25 09:55AM	Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors (Benzinga)
Aug-05-25 04:05PM	Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +5.74% -6.74%
Aug-04-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +5.12%
Jun-23-25 04:07PM	Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions (GlobeNewswire) -5.64%
May-29-25 04:05PM	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-14-25 09:30AM	Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 (GlobeNewswire)
May-09-25 07:54AM	Is Terns Pharmaceuticals, Inc. (TERN) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey)
May-08-25 04:05PM	Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -5.71%
Apr-30-25 04:05PM	Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference (GlobeNewswire) +6.11% +7.88%
Apr-26-25 08:50AM	Novo Nordisk: Examining Tariff And Pricing Risks (Seeking Alpha)
Apr-07-25 09:35AM	Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround (Zacks)
Apr-03-25 09:35AM	Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN) (Zacks) -6.43%
Apr-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Mar-26-25 12:00PM	All You Need to Know About Terns Pharmaceuticals (TERN) Rating Upgrade to Buy (Zacks) -6.63%
Mar-20-25 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates (GlobeNewswire) +6.69%
Mar-09-25 10:03AM	This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street (Motley Fool)
Feb-26-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Feb-25-25 08:05AM	Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference (GlobeNewswire)
03:00AM	Its CEO died. The company scrapped a promising program. Now, for their 2nd act. (Pharma Voice)
Feb-24-25 04:05PM	Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer (GlobeNewswire) -6.87%
Feb-20-25 04:05PM	Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors (GlobeNewswire)
Feb-05-25 04:05PM	Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-03-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-08-25 04:05PM	Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -6.84%
Jan-02-25 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Dec-16-24 01:10PM	Is Terns Pharmaceuticals, Inc. (TERN) the Best Weight Loss Stock to Buy Now According to Hedge Funds? (Insider Monkey)
Dec-03-24 07:00AM	Terns Pharmaceuticals Announces Positive Early Data from Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia (GlobeNewswire)
Dec-02-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Nov-18-24 04:05PM	Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors (GlobeNewswire) -7.62%
Nov-12-24 04:05PM	Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire) -5.44%
Nov-06-24 04:05PM	Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-07-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) -5.08%
Sep-24-24 03:22AM	Insiders Snap Up These 2 Strong Buy Stocks (TipRanks)
Sep-18-24 10:07AM	This Small-Cap Stock Has a Promising GLP-1 Drug That Could Rival Novo Nordisk's and Eli Lilly's Weight Loss Treatments (Motley Fool) +6.02%
Sep-17-24 01:30AM	OrbiMed Advisors LLC Increases Stake in Terns Pharmaceuticals Inc (GuruFocus.com)
Sep-15-24 07:21AM	Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. (Motley Fool)
06:09AM	Should You Invest in This Under-the-Radar Weight Loss Stock? (Motley Fool)
Sep-14-24 10:12AM	1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More (Motley Fool)
Sep-12-24 07:00PM	Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -10.96% -5.84%
Sep-10-24 10:50PM	Terns Announces Pricing of Upsized $150.15 Million Public Offering (GlobeNewswire) +23.14%
04:52AM	Terns Pharmaceuticals reports positive data from Phase I trial of obesity treatment (Clinical Trials Arena)
Sep-09-24 04:01PM	Terns Announces Proposed Public Offering (GlobeNewswire) +16.77%
09:58AM	Terns Pharmaceuticals Stock Is Soaring on Good Data for Weight-Loss Pill (Barrons.com)
09:24AM	Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month (Benzinga)
08:06AM	Early study data puts Terns among obesity drug contenders (BioPharma Dive)
07:05AM	Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity (GlobeNewswire)
Aug-28-24 09:55AM	Wall Street Analysts Think Terns Pharmaceuticals (TERN) Could Surge 78.74%: Read This Before Placing a Bet (Zacks)
Aug-05-24 09:56PM	TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024 (InvestorPlace)
04:05PM	Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
Aug-02-24 01:54PM	3 Biotech Stocks That Could Have Investors Grinning Soon (InvestorPlace)
Aug-01-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jul-29-24 04:05PM	Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition (GlobeNewswire) -7.55% -7.92%
Jul-26-24 06:40PM	Burger King Parent Company and More Stocks See Action From Activist Investors (Barrons.com)
Jul-20-24 09:30AM	Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? (Motley Fool)
Jun-21-24 06:30PM	Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA's 84th Annual Scientific Sessions and Upcoming Conference Participation (GlobeNewswire)
Jun-19-24 01:27PM	Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue? (Zacks)
Jun-04-24 09:55AM	Wall Street Analysts Believe Terns Pharmaceuticals (TERN) Could Rally 136.44%: Here's is How to Trade (Zacks)
Jun-03-24 04:10PM	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
May-30-24 08:05AM	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences (GlobeNewswire)
May-17-24 04:05PM	Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day (GlobeNewswire) +5.93%
May-13-24 01:53PM	TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024 (InvestorPlace) +5.94%
09:32AM	Terns Pharmaceuticals Inc (TERN) Q1 2024 Earnings: Misses Analyst Net Loss Projections (GuruFocus.com)
08:05AM	Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates (GlobeNewswire)
May-08-24 04:05PM	Terns Pharmaceuticals Announces Leadership Changes (GlobeNewswire) +5.03%
May-07-24 04:05PM	Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024 (GlobeNewswire)
May-03-24 04:05PM	Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire) +6.43%
Apr-29-24 04:05PM	Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation (GlobeNewswire)
Apr-10-24 04:05PM	Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer (GlobeNewswire) -5.23%
Mar-14-24 04:05PM	Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates (GlobeNewswire) -5.23% +7.30%

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Burroughs Amy L.	Chief Executive Officer	Jan 15 '26	Option Exercise	4.64	68,749	318,995	357,725	Jan 16 05:22 PM
Burroughs Amy L.	Chief Executive Officer	Jan 15 '26	Sale	37.07	68,749	2,548,603	288,976	Jan 16 05:22 PM
AMY BURROUGHS	Director	Jan 15 '26	Proposed Sale	37.18	97,915	3,640,480		Jan 15 04:24 PM
Burroughs Amy L.	Chief Executive Officer	Jan 02 '26	Option Exercise	4.64	21,551	99,997	60,315	Jan 06 08:26 PM
Burroughs Amy L.	Chief Executive Officer	Jan 05 '26	Sale	38.10	71,339	2,718,230	138,976	Jan 06 08:26 PM
Kuriakose Emil	Chief Medical Officer	Jan 02 '26	Sale	38.57	1,155	44,552	50,365	Jan 06 08:25 PM
Quigley Jill M.	Director	Nov 04 '25	Option Exercise	9.24	24,520	226,565	24,520	Nov 05 06:17 PM
Quigley Jill M.	Director	Nov 04 '25	Sale	18.00	24,520	441,360	0	Nov 05 06:17 PM
JILL QUIGLEY	Director	Nov 04 '25	Proposed Sale	14.03	24,520	344,016		Nov 04 04:32 PM
Kuriakose Emil	Chief Medical Officer	Oct 01 '25	Sale	7.85	944	7,407	51,520	Oct 02 07:24 PM
Kuriakose Emil	Chief Medical Officer	Jul 01 '25	Sale	4.27	853	3,640	52,464	Jul 03 02:55 PM
Gengos Andrew	Chief Financial Officer	Jun 27 '25	Buy	3.93	10,000	39,283	25,000	Jun 30 05:38 PM
Burroughs Amy L.	Chief Executive Officer	Jun 25 '25	Buy	3.87	23,314	90,230	47,083	Jun 25 06:08 PM
Gengos Andrew	Chief Financial Officer	Jun 13 '25	Buy	3.73	10,000	37,350	10,000	Jun 16 06:05 PM
Gengos Andrew	Chief Financial Officer	Jun 16 '25	Buy	3.95	5,000	19,732	15,000	Jun 16 06:05 PM
Kuriakose Emil	Chief Medical Officer	Apr 01 '25	Sale	2.49	952	2,366	53,317	Apr 02 06:48 PM

ARWR

Arrowhead Pharmaceuticals Inc

TERN

Terns Pharmaceuticals Inc

Upgrade your FINVIZ experience